444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101)
Publication
, Conference
Masuishi, T; Kuboki, Y; Fakih, MG; Strickler, JH; Furqan, M; Kim, EJ; Cardona, P; Tran, Q; Chan, E; Hong, DS
Published in: Annals of Oncology
September 2022
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2022
Volume
33
Start / End Page
S737 / S738
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Masuishi, T., Kuboki, Y., Fakih, M. G., Strickler, J. H., Furqan, M., Kim, E. J., … Hong, D. S. (2022). 444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101). In Annals of Oncology (Vol. 33, pp. S737–S738). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.1865
Masuishi, T., Y. Kuboki, M. G. Fakih, J. H. Strickler, M. Furqan, E. J. Kim, P. Cardona, Q. Tran, E. Chan, and D. S. Hong. “444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101).” In Annals of Oncology, 33:S737–38. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.1865.
Masuishi T, Kuboki Y, Fakih MG, Strickler JH, Furqan M, Kim EJ, et al. 444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101). In: Annals of Oncology. Elsevier BV; 2022. p. S737–8.
Masuishi, T., et al. “444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101).” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S737–38. Crossref, doi:10.1016/j.annonc.2022.07.1865.
Masuishi T, Kuboki Y, Fakih MG, Strickler JH, Furqan M, Kim EJ, Cardona P, Tran Q, Chan E, Hong DS. 444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101). Annals of Oncology. Elsevier BV; 2022. p. S737–S738.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2022
Volume
33
Start / End Page
S737 / S738
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis